Drug profile · INN
linerixibat
LYNAVOY
linerixibat (LYNAVOY) is a ileal bile acid transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — linerixibat
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
linerixibat (LYNAVOY) is a ileal bile acid transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Ileal bile acid transporter inhibitor
Primary target: Ileal sodium/bile acid cotransporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is linerixibat?
linerixibat (LYNAVOY) is a ileal bile acid transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for linerixibat?
LYNAVOY is a marketed brand name for linerixibat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of linerixibat?
linerixibat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.